Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 7,622,070 | 920,774 | 2,089,719 | 4,401,024 | 3,151,961 |
| Marketable Securities | 1,418,902 | 691,163 | 2,640,026 | 3,001,322 | 2,547,399 |
| Receivables | 10,985,560 | 10,446,800 | 10,927,900 | 9,046,744 | 10,303,120 |
| Inventories | 5,246,171 | 4,892,160 | 4,618,957 | 4,311,964 | 4,093,722 |
| Other current assets | 340,547 | 2 | -2 | -4 | -2 |
| TOTAL | $25,613,250 | $16,950,900 | $20,276,600 | $20,761,050 | $20,096,200 |
| Non-Current Assets | |||||
| PPE Net | 15,870,110 | 14,302,290 | 13,207,540 | 11,893,310 | 10,961,010 |
| Investments And Advances | 239,394 | 240,386 | 241,468 | 214,766 | 216,082 |
| Intangibles | 8,008,794 | 8,683,584 | 8,770,951 | 8,135,996 | 7,414,429 |
| Other Non-Current Assets | 3,570,422 | 3,345,740 | 3,166,811 | 2,809,618 | 2,330,289 |
| TOTAL | $27,688,720 | $26,572,000 | $25,386,770 | $23,053,690 | $20,921,810 |
| Total Assets | $53,301,970 | $43,522,900 | $45,663,370 | $43,814,750 | $41,018,010 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 786,724 | 1,479,878 | 940,606 | 965,498 | 918,823 |
| Accounts payable and accrued liabilities | 4,294,224 | 1,893,674 | 3,717,991 | 2,935,476 | 2,598,827 |
| Other current liabilities | 21,182,090 | 19,870,320 | 18,942,070 | 19,496,260 | 17,959,200 |
| TOTAL | $27,115,270 | $24,112,230 | $24,633,910 | $25,192,590 | $22,881,890 |
| Non-Current Liabilities | |||||
| Long Term Debt | 7,447,034 | 2,440,838 | 2,980,666 | 2,908,904 | 2,836,531 |
| Other Non-Current Liabilities | 1,198,700 | 1,161,306 | 1,100,616 | 985,354 | 967,182 |
| TOTAL | $9,949,773 | $5,009,222 | $5,556,804 | $5,045,468 | $4,918,018 |
| Total Liabilities | $37,065,040 | $29,121,460 | $30,190,710 | $30,238,060 | $27,799,910 |
| Shareholders' Equity | |||||
| Common Shares | 64,358 | 65,666 | 65,485 | 65,846 | 65,891 |
| Retained earnings | 16,183,250 | 14,421,680 | 15,222,620 | 13,393,310 | 12,874,040 |
| Other shareholders' equity | -10,688 | -84,906 | 185,555 | 118,534 | 278,179 |
| TOTAL | $16,236,920 | $14,401,440 | $15,472,660 | $13,576,690 | $13,218,110 |
| Total Liabilities And Equity | $53,301,960 | $43,522,900 | $45,663,370 | $43,814,750 | $41,018,020 |